# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
REM-001 Clinical Study UpdateAs of September 10, 2024, the REM-001 study in patients with cutaneous metastatic breast cancer (C...
Stockholders must vote by 11:59 p.m., Eastern Time, on September 19, 2024, for their vote to count
KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel t...